In the SURMOUNT-1 trial, tirzepatide produced mean weight reductions of 15.0%, 19.5% and 20.9% at 5 mg, 10 mg and 15 mg respectively by week 72, compared with 3.1% on placebo. Most of that loss accumulated across the first six to nine months, and a post-hoc analysis found the median time to weight plateau was between 24 and 36 weeks depending on starting BMI. One point has to be made before any timeline makes sense: Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. Zepbound is the tirzepatide product approved for chronic weight management, and the weight-loss trial data below comes from that development programme. Using Mounjaro for weight reduction alone is off-label. This article is educational and is not medical advice. Advanced TRT Clinic is not affiliated with or endorsed by Eli Lilly.
Which Tirzepatide Product This Question Is Actually About
Searches for a Mounjaro weight loss timeline run into a labeling distinction straight away, and skipping it produces a misleading answer.
Mounjaro and Zepbound contain the same molecule — tirzepatide, a dual GIP and GLP-1 receptor agonist — from the same manufacturer, in the same style of once-weekly injection, on the same dose ladder. What differs is the indication each was approved under, and that difference has practical consequences.
| Parameter | Mounjaro | Zepbound |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide — the same molecule |
| FDA-approved indication | Type 2 diabetes in adults and in children aged 10 and over | Chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity |
| Use for weight loss alone | Off-label | On-label |
| Pivotal trial programme | SURPASS — glycemic control in type 2 diabetes, weight as a secondary endpoint | SURMOUNT — weight reduction as the primary endpoint |
| Labeled reason to escalate | Additional glycemic control | Additional weight reduction |
The word off-label is not a synonym for improper. Prescribing a medication outside its approved indication is lawful and common, and it remains a decision for a licensed clinician who has assessed the individual patient. But it changes three practical things: insurance coverage is usually harder to obtain, manufacturer savings programmes are generally tied to the on-label product, and the dose rationale written into the labeling refers to glycemic targets rather than weight.
The timeline below is drawn from the SURMOUNT programme, because those trials measured weight reduction as the primary outcome. Mounjaro’s own programme, SURPASS, measured HbA1c first. In SURPASS-2, adults with type 2 diabetes on metformin lost a mean of 7.6 kg, 9.3 kg and 11.2 kg at 5 mg, 10 mg and 15 mg over 40 weeks — a different population, duration and endpoint from the obesity trials.
The Dose Schedule Sets the Pace
Before looking at results by week, it helps to understand that the first several months are largely consumed by titration. This is the single most common source of disappointed expectations.
Tirzepatide starts at 2.5 mg once weekly. That dose is explicitly a starting dose intended to reduce gastrointestinal adverse reactions — it is not considered a therapeutic maintenance dose. After four weeks it may be increased in 2.5 mg steps, and each step requires at least four weeks before the next.
| Weeks | Weekly dose | What this step is for |
|---|---|---|
| 1–4 | 2.5 mg | Starting dose for tolerability, not a treatment dose |
| 5–8 | 5 mg | First dose studied as a maintenance dose in SURMOUNT-1 |
| 9–12 | 7.5 mg | Intermediate titration step |
| 13–16 | 10 mg | Second maintenance dose studied in SURMOUNT-1 |
| 17–20 | 12.5 mg | Intermediate titration step |
| 21 onward | 15 mg | Maximum labeled dose; highest dose studied |
Two implications follow. The earliest anyone reaches 15 mg on this schedule is around week 21, so roughly the first five months are spent approaching the dose rather than sitting at it. And many patients never reach 15 mg, because escalation continues only while it is both tolerated and clinically indicated. A clinician may hold a patient at 7.5 mg or 10 mg indefinitely if the response is adequate or the side effects are not.
Gastrointestinal adverse reactions cluster around dose increases. Extending time at a step, or stepping back down, is a recognised way of managing them and is written into the prescribing information as the rationale for gradual titration. A patient who takes eight months to reach a dose that someone else reached in five has not fallen behind — they have followed a schedule their clinician judged appropriate. Our guide to tirzepatide side effects covers what tends to appear at each step.
What the Trial Timeline Actually Looked Like
SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI of 30 or above, or 27 or above with a weight-related complication. Mean baseline weight was 104.8 kg. Participants were randomised to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks alongside lifestyle intervention, with all tirzepatide arms escalating from 2.5 mg in 2.5 mg steps every four weeks.
The trial reported outcomes at fixed timepoints rather than week by week, so the phases below describe the shape of the curve rather than a guaranteed weekly schedule.
The Four Phases of the Trial Trajectory
Derived from the SURMOUNT-1 escalation protocol and the published plateau analysis
| WEEKS 1–4 | WEEKS 5–20 | WEEKS 20–36 | WEEKS 36–72 |
|
Starting dose 2.5 mg weekly Appetite change often noticed Weight change usually modest GI symptoms most prominent |
Escalation 5 mg through 12.5 mg Steepest part of the curve Symptoms recur at each step Most visible period of change |
Approaching plateau Maintenance dose reached Rate of loss begins slowing Median plateau falls in this window Tolerability usually improved |
Plateau and maintenance Curve substantially flattened Most participants had plateaued Primary endpoint read at week 72 Focus shifts to maintaining |
Figure 1. Educational summary of the trial trajectory. Phases are not a schedule any individual should expect to follow, and timing varied considerably between participants.
Weeks 1 to 4 — the starting dose. At 2.5 mg, the dose is below the levels studied as maintenance doses. Many participants notice reduced appetite and earlier fullness within the first weeks, but substantial weight change this early is not the expectation. Gastrointestinal adverse reactions — nausea, diarrhoea, constipation — were most prominent during escalation, and the first dose is where many people meet them.
Weeks 5 to 20 — escalation. This is the steepest part of the curve for most participants. The dose rises through 5 mg, 7.5 mg, 10 mg and 12.5 mg, and each increase tends to produce a renewed appetite effect along with a renewed round of gastrointestinal symptoms that usually settles within one to two weeks.
Weeks 20 to 36 — approaching the plateau. By around week 21 a patient escalating without interruption would be at 15 mg. The rate of weight loss typically begins to slow in this window, and for a substantial proportion of SURMOUNT-1 participants the plateau fell inside it. Tolerability generally improves once the dose stops changing.
Weeks 36 to 72 — plateau and maintenance. Weight continues to decline for many participants, but far more slowly. SURMOUNT-1 read its primary endpoint at week 72, and the figures below are from that timepoint.
| Outcome at week 72 | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Mean weight change | −15.0% | −19.5% | −20.9% | −3.1% |
| Achieved ≥5% reduction | 85.1% | 88.9% | 90.9% | 34.5% |
| Achieved ≥20% reduction | 30.0% | 50.1% | 56.7% | 3.1% |
| Waist circumference change | −14.0 cm | −17.7 cm | −18.5 cm | −4.0 cm |
| Discontinued due to adverse events | 4.3% | 7.1% | 6.2% | 2.6% |
All weight comparisons against placebo were statistically significant. Every figure in this table is a group average or proportion from one trial population, and none of them is a prediction for an individual.
When Weight Loss Plateaus
The plateau is the part of the timeline most people are actually asking about, and until recently it was described mainly anecdotally. A 2025 post-hoc analysis published in Clinical Obesity examined it directly in SURMOUNT-1 and SURMOUNT-4.
The authors defined a plateau as a weight change of less than 5% across a 12-week interval and across every later 12-week interval — in other words, the point after which the curve genuinely stops moving rather than briefly pausing. The analysis included 1,438 SURMOUNT-1 participants and 259 from SURMOUNT-4, restricted to those who stayed on treatment and had lost at least 5% of body weight by the primary endpoint.
Median Time to Weight Plateau by Baseline BMI Category
SURMOUNT-1 post-hoc analysis, adherent participants with at least 5% reduction
| Overweight (BMI 27–29.9) | 24.3 wk | |
| Class I obesity (BMI 30–34.9) | 26.0 wk | |
| Class II obesity (BMI 35–39.9) | 36.1 wk | |
| Class III obesity (BMI 40+) | 36.1 wk |
Figure 2. Median values from Horn et al., Clinical Obesity 2025. Class II and class III differed significantly from the overweight group. A median means half of participants plateaued earlier and half later.
Three findings are worth holding on to. Participants who started at a higher BMI took longer to plateau. The higher doses — 10 mg and 15 mg — were associated with a later plateau than lower doses, as were younger age and female sex. And by week 72, between roughly 88% and 90% of participants across the BMI categories had plateaued.
A plateau is the expected shape, not a failure. Nearly nine in ten adherent participants reached one inside 72 weeks. It is what the curve does, not a sign the medication stopped working.
Starting BMI shifts the timing. Median time to plateau was about 24 weeks in the overweight group and about 36 weeks in class II and class III obesity.
Half of participants fell on each side of the median. A median of 36 weeks means a substantial number plateaued considerably earlier and a substantial number considerably later.
The analysis studied people who stayed on treatment. It was restricted to adherent participants who had lost at least 5%, so it describes the trajectory of treatment that continued, not of treatment generally.
Why an Individual Timeline Will Not Match the Trial Average
Every figure above is a group mean. Translating one into a personal forecast is where most week-by-week content goes wrong.
Averages conceal a wide distribution. At 15 mg, 56.7% of participants reached a 20% reduction by week 72 — which also means 43.3% did not, and some lost considerably less. The spread around a mean of 20.9% is substantial in both directions.
Reported figures depend on the statistical approach. SURMOUNT-1 reported results under more than one analysis. The 20.9% quoted throughout this article is the treatment-regimen estimand, which counts everyone randomised including participants who stopped early or did not reach the target dose. An efficacy estimand restricted to those who remained on treatment as planned produced a higher figure. Neither is wrong, but figures from the two analyses are not interchangeable, and coverage frequently quotes the higher number without saying which it is.
Escalation pace and baseline characteristics differ. Trial participants escalated on protocol and received structured lifestyle intervention throughout; outside a trial, clinicians hold doses, step back down and extend intervals in response to tolerability. The plateau analysis also found starting BMI, age and sex all associated with timing.
Advanced TRT Clinic provides administrative and technology services to a clinical practice that offers paid weight management services. That is a commercial interest, and readers should weigh this article accordingly. Nothing here is a recommendation to begin, continue, delay or stop any treatment, and the trial figures presented are group averages from controlled studies rather than results you should expect. For a wider view of how the drug class compares, see our complete GLP-1 class overview.
What the Data Shows About Stopping
SURMOUNT-4 was designed to answer this question directly, and it is the other half of any honest timeline.
783 participants received open-label tirzepatide for 36 weeks, escalating to a maximum tolerated dose of 10 mg or 15 mg. At the end of that lead-in, mean weight reduction was 20.9%. 670 participants were then randomised either to continue tirzepatide or to switch to placebo for a further 52 weeks.
Those who continued lost a further 5.5% on average, reaching 25.3% total reduction at week 88. Those switched to placebo regained 14.0%, finishing at 9.9% below their original baseline. At week 88, 89.5% of the continued-treatment group still retained at least 80% of the weight they had lost during the lead-in, compared with 16.6% of the placebo group.
The finding is consistent with how obesity is characterised in current clinical guidance — as a chronic condition in which the physiological drivers of weight regain persist after treatment stops. It is a trial result rather than an argument, and what any individual should do with it is a question for their clinician. Our guide to safe use of tirzepatide covers the monitoring that accompanies longer-term therapy.
Safety Information and When to Seek Care
In rodent studies, tirzepatide caused dose-dependent thyroid C-cell tumors. It is unknown whether it causes medullary thyroid carcinoma (MTC) in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other reported risks include pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury, hypoglycemia when combined with insulin or a sulfonylurea, and gastrointestinal adverse reactions. Report any new neck lump, hoarseness, difficulty swallowing, or severe abdominal pain to a physician immediately.
Seek medical attention without delay for severe abdominal pain, particularly pain radiating to the back; persistent vomiting or an inability to keep fluids down; signs of severe dehydration; yellowing of the skin or eyes; swelling of the face, lips or throat; or difficulty breathing.
Separately, tirzepatide supplied in a vial with a syringe, or described as compounded, research-grade or not for human use, sits outside the legal supply chain. Identity, concentration and sterility cannot be verified, and dosing errors have been reported with such products.
Get a Physician Evaluation for Weight Management
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring. Clinicians can determine whether a tirzepatide product is appropriate, which product and indication apply, how escalation should be paced, and what monitoring is needed. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions, and is not affiliated with, endorsed by, or a distributor for Eli Lilly or Novo Nordisk. No specific clinical outcome, degree of weight loss, insurance approval, or medication availability is guaranteed. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment, within their scope of practice and applicable state law. Availability varies by state.
